What a month!

The Yale Innovation Summit had a record-breaking year. Over two days, more than 1000 attendees from 320+ companies and 120 VC firms joined us in New Haven. And we have the photos to prove it! Check out the gallery here. 

May also brought some big news across the New Haven innovation ecosystem. Yale spinout Biohaven was acquired by Pfizer with plans to maintain and likely expand their New Haven presence. Congratulations to Vlad Coric and his entire team. In addition, Irish biotechnology / AI company Nuritas announced it will build its North American headquarters in New Haven. Welcome to Connecticut, Dr. Nora Khaldi.

Check out all the news from this month, and what's coming down the pike in this month's Yale Ventures Report. 

Josh Geballe

Managing Director, Yale Ventures

Yale Innovation Summit celebrates thriving bioscience sector, seeks new alpha

Why New Haven? “The pizza?” ventured Nora Khaldi, to laughs from a packed house at Tuesday’s Yale Innovation Summit at the Omni New Haven Hotel...

New SEAS fund will help nurture Yale-borne ideas that benefit humankind. A Q&A with Dean Jeffrey Brock

The newly created Roberts Innovation Fund will improve the chances that world-changing advances by these and other researchers at SEAS will reach market and help address some of the world’s most pressing challenges.

Connecticut looks to shed ‘white picket fence, stone wall’ image as it promotes life science industry

The inaugural "State of the Life Sciences Report" co-authored by AdvanceCT, BioCT, and Yale Ventures 

Panel (Trends in Biotech Investing): Despite ‘pruning’ during downturn, expect continued bioscience growth

New Hire News! 

Jennifer Beecham has joined Yale Ventures as Associate Director for the Blavatnik Fund for Innovation at Yale University. Jenn joins us from Reata Pharmaceuticals, Inc. where she held a variety of roles including corporate strategy, market research, commercial launch planning, and marketing. Welcome to the Yale Ventures team, Jenn!